Ongoing safety check for mastocytosis drug avapritinib

NCT ID NCT06748001

Recruiting now Disease control Sponsor: Blueprint Medicines Corporation Source: ClinicalTrials.gov ↗

First seen Dec 10, 2025 · Last updated May 23, 2026 · Updated 24 times

Summary

This study is for people with systemic mastocytosis who are already taking avapritinib and benefiting from it. It aims to track long-term safety by monitoring serious side effects. About 60 participants will continue their current treatment and be followed over time. No new drug or treatment is being tested.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MASTOCYTOSIS, SYSTEMIC are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

A.O.U. San Giovanni di Dio e Ruggi d'Aragona di Salerno
RECRUITING

Salerno, 84131, Italy
Erasmus Medisch Centrum
RECRUITING

Rotterdam, 3015, Netherlands
Guys and St Thomas NHS Foundation Trust - St Thomas Hospital
RECRUITING

London, SE19RT, United Kingdom
Oslo University Hospital
RECRUITING

Oslo, 0424, Norway
The Hospital for Sick Children
RECRUITING

Toronto, Ontario, M5G 1X8, Canada
Universitair Medisch Centrum Groningen
RECRUITING

Groningen, 9700, Netherlands
Universitair Ziekenhuis Antwerpen (UZA)
RECRUITING

Edegem, 2650, Belgium

Conditions

Explore the condition pages connected to this study.

MASTOCYTOSIS, SYSTEMIC